Rani Therapeutics Holdings, Inc is a clinical stage biotherapeutics company focused on enabling oral administration of biologics and drugs. The company has developed a proprietary drug agnostic oral delivery platform known as the RaniPill capsule. The platform comes in two configurations the RaniPill GO for solid microtablet doses up to three milligrams and the RaniPill HC for liquid payloads up to two hundred microliters. Each product candidate consists of a RaniPill capsule containing a specific biologic such as a GLP 1 GLP 2 dual agonist semaglutide adalimumab ustekinumab or other therapeutic molecules. The company conducts preclinical studies and clinical trials to demonstrate bioavailability comparable to subcutaneous injection. It also pursues partnerships with third party biopharma firms to expand the use of its technology.

The company has not yet generated revenue from sales of a commercial product because no product has received regulatory approval. Revenue is derived primarily from collaboration and license agreements that include upfront payments technology transfer milestones development milestones sales based milestones and royalties on net sales. For example the October 2025 agreement with Chugai Pharmaceutical provided a ten million dollar upfront fee and potential additional payments contingent on progress of the oral hemophilia product. Similar arrangements with ProGen and Celltrion provide upfront cash and future milestone opportunities. These collaboration revenues support operations while the pipeline advances toward potential commercialization.

Rani Therapeutics Holdings, Inc occupies a niche within the broader biologics delivery landscape as one of few firms pursuing an oral route for large molecules. Its main competitors include established injectable biologics manufacturers such as AbbVie Eli Lilly Johnson & Johnson and emerging oral delivery groups like Novo Nordisk with its oral semaglutide product and chemistry based firms such as Oramed Entera Bio Protagonist Therapeutics and Intract Pharma. Other device based efforts include the SOMA and LUMI platforms from the Novo Nordisk MIT collaboration and early stage companies Biograil Biora and Alma Therapeutics. The company differentiates itself through demonstrated high bioavailability and dosing accuracy a drug agnostic design that accommodates molecules ranging from small peptides to large proteins and a vertical integration manufacturing approach that protects intellectual property and enables rapid iteration. These attributes give Rani a potential advantage in delivering biologics that currently rely on injection and in addressing patient aversion to needles. The platform also demonstrates reliable performance in both fed and fasted states which improves dosing flexibility for patients.

The company serves patients with chronic diseases who require biologics such as those for obesity autoimmune disorders and hemophilia. Physicians and healthcare systems represent the eventual prescribers and administrators of any approved oral product. In the precommercial phase Rani collaborates with biopharma partners that supply drug substance and share development costs and risks. Notable partners include Chugai Pharmaceutical which provides a hemophilia targeting compound ProGen which supplies a GLP 1 GLP 2 dual agonist and Celltrion which supplies biosimilar versions of adalimumab and ustekinumab. These relationships provide access to active pharmaceutical ingredients and validation of the platform while expanding the potential market reach of the technology.